ReCode Therapeutics Announces Additional Funding From the Cystic Fibrosis Foundation Nia JulianNovember 19, 2024
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics Nia JulianOctober 31, 2024
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis Nia JulianFebruary 15, 2024
EvolveImmune Therapeutics Provides Corporate and Program Update Highlighted by Closing of $37 Million Financing Nia JulianDecember 21, 2023
Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines Nia JulianJanuary 5, 2023
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma Nia JulianDecember 12, 2022
AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline Nia JulianDecember 6, 2022
Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies Nia JulianSeptember 21, 2022
Kezar's phase 2 lupus data spur hope for former pipeline-in-a-drug contender—and a share rally Nia JulianJune 29, 2022
Carbon Biosciences emerges with a new viral vector to shake up the cystic fibrosis gene therapy field Nia JulianJune 21, 2022
ASCO: ‘Any way you slice’ it, Arcellx's CAR-T is matching J&J-Legend’s Carvykti, analyst says Nia JulianJune 9, 2022
Arcellx raises $124M in Wall Street debut to bankroll study of multiple myeloma CAR-T Nia JulianFebruary 8, 2022
Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology Nia JulianJanuary 11, 2022
